Anavex Life Sciences Corp. (AVXL)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Anavex Life Sciences Corp. (AVXL) is down 25.7% since the beginning of the year. At $3 per share, AVXL is trading 81.1% below its 52-week high of $14. Investors who bought $1,000 worth of AVXL shares 5 years ago would now be looking at an investment worth $195.

Anavex Life Sciences Corp. (AVXL) has returned -25.70% so far this year and -66.26% over the past 12 months. Over the last ten years, AVXL has returned -5.28% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Aug 2, 2006, AVXL's average daily return is +0.13%, while the average monthly return is +1.87%. At this rate, an investment would double in approximately 3.1 years.

Historically, 49% of months were positive and 51% were negative. The best month was Feb 2021 with a return of +107.3%, while the worst month was Sep 2008 at -57.5%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 5 months.

On a daily basis, AVXL closed higher 43% of trading days. The best single day was Nov 18, 2015 with a return of +63.6%, while the worst single day was Jul 27, 2016 at -40.5%.

Anavex Life Sciences Corp. has an annualized alpha of 30.46%, beta of 0.67, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since August 03, 2006.

• This stock participated in 83.81% of S&P 500 Index downside but only 25.92% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.67 may look defensive, but with R2 of 0.02 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

AVXL ranks 11 for risk / return — in the bottom 11% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Anavex Life Sciences Corp. (AVXL) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Anavex Life Sciences Corp.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Anavex Life Sciences Corp. was 97.06%, occurring on Nov 19, 2014. Recovery took 1655 trading sessions.

The current Anavex Life Sciences Corp. drawdown is 90.84%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Anavex Life Sciences Corp. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Anavex Life Sciences Corp. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.